DXCM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.3B
+2.8%
1.3B
+9.8%
1.2B
-5.4%
1.3B
+4.2%
1.2B
Cost of Revenue
480.1M
+0.4%
478.4M
+8.3%
441.6M
-5.4%
466.9M
-2.3%
477.9M
Gross Profit
864.4M
+4.1%
830.0M
+10.6%
750.3M
-5.3%
792.7M
+8.4%
731.4M
Operating Expenses
537.2M
+5.0%
511.7M
+3.4%
495.0M
+5.4%
469.7M
-3.9%
488.9M
R&D
161.6M
+5.6%
153.0M
+5.3%
145.3M
-2.0%
148.2M
-5.9%
157.5M
SG&A
375.6M
+4.7%
358.7M
+2.6%
349.7M
+8.8%
321.5M
-3.0%
331.4M
Operating Income
327.2M
+2.8%
318.3M
+24.7%
255.3M
-21.0%
323.0M
+33.2%
242.5M
EBITDA
401.7M
+3.9%
386.5M
+19.9%
322.4M
-17.0%
388.2M
+26.8%
306.1M
Net Income
275.1M
+10.4%
249.1M
+24.9%
199.5M
-25.4%
267.3M
-5.8%
283.8M
EPS (Basic)
$0.73
+12.3%
$0.65
+25.0%
$0.52
-24.6%
$0.69
-5.5%
$0.73
EPS (Diluted)
$0.72
+12.5%
$0.64
+25.5%
$0.51
-23.9%
$0.67
-4.3%
$0.70
Shares (Diluted)
383.5M
-1.7%
390.1M
-0.9%
393.6M
-1.3%
398.9M
-2.1%
407.4M
DexCom (DXCM) — Financials